170 related articles for article (PubMed ID: 35870306)
1. Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions.
Jahn B; Santamaria J; Dieplinger H; Binder CJ; Ebenbichler C; Scholl-Bürgi S; Conrads-Frank A; Rochau U; Kühne F; Stojkov I; Todorovic J; James L; Siebert U
Atherosclerosis; 2022 Aug; 355():15-29. PubMed ID: 35870306
[TBL] [Abstract][Full Text] [Related]
2. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
[TBL] [Abstract][Full Text] [Related]
3. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
[TBL] [Abstract][Full Text] [Related]
4. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review.
Rosso A; Pitini E; D'Andrea E; Massimi A; De Vito C; Marzuillo C; Villari P
Ann Ig; 2017; 29(5):464-480. PubMed ID: 28715059
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
[TBL] [Abstract][Full Text] [Related]
6. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
[TBL] [Abstract][Full Text] [Related]
7. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
Crosland P; Maconachie R; Buckner S; McGuire H; Humphries SE; Qureshi N
Atherosclerosis; 2018 Aug; 275():80-87. PubMed ID: 29879685
[TBL] [Abstract][Full Text] [Related]
9. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA
Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of cost-effectiveness analysis of different screening strategies for familial hypercholesterolemia.
Meng R; Wei Q; Zhou J; Zhang B; Li C; Shen M
J Clin Lipidol; 2024; 18(1):e21-e32. PubMed ID: 37980172
[TBL] [Abstract][Full Text] [Related]
11. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
[TBL] [Abstract][Full Text] [Related]
12. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review.
Marquina C; Morton JI; Lloyd M; Abushanab D; Baek Y; Abebe T; Livori A; Dahal P; Watts GF; Ademi Z
Pharmacoeconomics; 2024 Apr; 42(4):373-392. PubMed ID: 38265575
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.
Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL
J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and Return on Investment of a Nationwide Case-Finding Program for Familial Hypercholesterolemia in Children in the Netherlands.
Ademi Z; Norman R; Pang J; Sijbrands E; Watts GF; Hutten BA; Wiegman A
JAMA Pediatr; 2023 Jun; 177(6):625-632. PubMed ID: 37126315
[TBL] [Abstract][Full Text] [Related]
16. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis.
Marquina C; Lacaze P; Tiller J; Riaz M; Sturm AC; Nelson MR; Ference BA; Pang J; Watts GF; Nicholls SJ; Zoungas S; Liew D; McNeil J; Ademi Z
Eur Heart J; 2022 Sep; 43(34):3243-3254. PubMed ID: 34788414
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
Chen CX; Hay JW
Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
[TBL] [Abstract][Full Text] [Related]
18. Parental Attitudes and Ideas Regarding Newborn Screening for Familial Hypercholesterolemia.
Tobik K; Orland KM; Zhang X; Garcia K; Peterson AL
Matern Child Health J; 2023 Jun; 27(6):978-983. PubMed ID: 36964843
[TBL] [Abstract][Full Text] [Related]
19. Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review.
Groselj U; Kovac J; Sustar U; Mlinaric M; Fras Z; Podkrajsek KT; Battelino T
Atherosclerosis; 2018 Oct; 277():383-391. PubMed ID: 30270075
[TBL] [Abstract][Full Text] [Related]
20. Reverse Cascade Screening for Familial Hypercholesterolemia.
Vinson A; Guerra L; Hamilton L; Wilson DP; Fnla
J Pediatr Nurs; 2019; 44():50-55. PubMed ID: 30683281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
